Compare Jones Lang LaSalle Inc (JLL) vs Sana Biotechnology Inc (SANA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Jones Lang LaSalle Inc vs Sana Biotechnology Inc — how do they compare? Jones Lang LaSalle Inc trades at $299.87 (market cap $13.95B), while Sana Biotechnology Inc trades at $2.79 (market cap $836.71M). The key difference: Jones Lang LaSalle Inc is far larger — about 16.7× Sana Biotechnology Inc's market cap, and Jones Lang LaSalle Inc is trading nearer its 52-week high, Sana Biotechnology Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Jones Lang LaSalle Inc for 71 Days and Sana Biotechnology Inc for 23 Days on average.
| JLL | SANA | |
|---|---|---|
Market Cap | $13.95B | $836.71M |
Volume | 457,462 | 4,507,444 |
Sector | Real Estate | Health |
52-Week High | $392.79 | $5.92 |
52-Week Low | $280.16 | $2.68 |
Typical Hold Time | 71 Days | 23 Days |
Enterprise Value | $16.71B | $749.96M |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
JLL trades at $303.14, up 2.18% today, with a bearish technical signal but strong fundamentals. The stock has beaten EPS estimates in recent quarters, with Q3 2026 results pending. Revenue grew to $26.12B in 2025, and net income improved to $792.10M. Analyst consensus is bullish with a $450.50 price target, though technical indicators show resistance near $307.
Outlook remains positive due to earnings momentum and strategic acquisitions, but risks include market volatility and competitive pressures. The stock offers value with a P/E of 14.54 and ROE of 13.78%, supported by institutional interest and growth in real estate services.
SANA Biotechnology trades at $2.79, up 2.57% today, but faces significant fundamental challenges with negative revenue, substantial losses, and bearish technical indicators. The company reported a net loss of $244.17 million in 2025 with no revenue, while technical analysis shows a bearish trend with moving averages and ADX indicators signaling selling pressure. Recent news highlights multiple investor conference presentations and ongoing legal scrutiny regarding fiduciary duties.
Despite strong analyst support (82% buy ratings), SANA's lack of revenue generation and negative profitability metrics present substantial investment risk. The company's cash flow remains negative, requiring continued financing. Near-term catalysts include upcoming Q3 earnings and clinical developments, but investors should weigh the high-risk profile against potential long-term biotechnology breakthroughs.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Jones Lang LaSalle Inc
Jones Lang LaSalle provides a wide range of real estate-related services to owners, occupiers, and investors worldwide, including leasing, property and project management, and capital markets advisory. JLL's investment management arm, LaSalle Investment Management, manages over $70 billion for clients across diverse public and private real estate strategies.
Read more on JLL →About Sana Biotechnology Inc
Sana Biotechnology Inc. is a clinical-stage biopharmaceutical company focused on creating and delivering engineered cells as medicines for patients. The company is developing cell therapies for various diseases, including oncology, diabetes, and central nervous system disorders. Sana's core strategy is built around two key technological platforms: in vivo gene delivery to repair cells inside the body and ex vivo cell engineering for therapeutic use.
Read more on SANA →
